Zensar reports 8.6% YoY revenue growth for Q3FY25

Citation

RPG Life Sciences Limited has announced its financial results for the third quarter and nine months ended December 31, 2024.

RPG Life Sciences, a part of RPG Enterprises, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT before exceptional items by 32% Y-o-Y and by 11% Q-o-Q for Q3 FY25, maintaining the upward trajectory in EBITDA margins, which improved from 25.9% to 30.4% Y-o-Y and from 27.8% to 30.4% Q-o-Q. Revenue from operations registered a growth of 12% Y-o-Y and a flat growth Q-o-Q for Q3 FY25. For 9M FY25 too, the company posted a jump in PBT before exceptional items by 25% Y-o-Y and recorded EBITDA margin expansion from 24.8% to 27.8% Y-o-Y. Revenue from operations at Rs. 510.34 crores registered a growth of 12% Y-o-Y for 9M FY25.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q3 FY25, the overall performance of the Company continued to be strong. Revenue and PBT grew by 12% and 32% respectively Y-o-Y. EBITDA margin surged from 25.9% to 30.4% Y-o-Y retaining its upward trajectory Y-o-Y for the last more than 5 years. The Company continues to remain debtfree.

Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market basis the five pillar strategy – product portfolio rejuvenation, building strategic brand/portfolio assets, sales force excellence and productivity enhancement, customer engagement through medico-marketing initiatives and continued cost efficiency drive.

We are now shaping our International Formulations and API businesses to emerge as second and third growth engines. For this to happen, while we are on course to modernize both our API and Formulations plants - by infusion of significant capex, our modernized R&D laboratories are also working to build a smart product pipeline. The International Formulations business is now registering healthy double-digit growth, and the API business is also showing promising growth.

Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted Y-o-Y margin expansion trajectory.

Cash that would be generated by assignment of surplus vacant leasehold land at our Navi Mumbai plant will add to our existing cash surplus which we are actively working to deploy gainfully for business expansion.”

RPG Life Sciences Ltd (www.rpglifesciences.com):
RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a researchbased pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Group (www.rpggroup.com):
RPG Group, established in 1979, is one of India’s fastest growing business groups with a turnover of US$ 4.8 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.